CUA Educational Content

Drug Access Listing: Advanced Prostate Cancer

With the expanded armamentarium of oral therapies for management of advanced prostate cancer, urology-oncology specialists have more options to consider for their patients. Access to these important therapies through provincial public funding or patient support programs is evolving and can be challenging for prescribers to uncover and navigate.

To assist physicians in identifying public and patient support program access mechanisms, the CUA has developed a drug listing of oral prostate cancer therapies and relevant outpatient injectables (e.g. bone health agents) with provincial funding criteria and support program details (e.g. criteria, contacts, weblinks) organized by province.

CLICK MAP TO VIEW:

The Canadian Urological Association (CUA) does not provide professional medical advice, diagnosis or treatment and cannot respond to requests for direct feedback, specific patient information or physician referrals. You should first always seek the advice of your urologist, physician and other qualified health provider with any questions regarding your medical condition. The contents of the CUA Website such as text, graphics, images, and other content are for informational purposes only. The content/information is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on the CUA website.

For comments or information, email Corporate.office@cua.org